The most comprehensive solution for cytogenetics and molecular genetics in one system for analysis and interpretation of all genomic variants from microarray and NGS data.

Request Demo

Features and Benefits

Automatically builds a case history of all samples analyzed
Customized workflows with adherence to ACMG or other guidelines
Multi-user system with audit trail and global accessibility
Maintains data fidelity with a secure, central database
Single test paradigm – CNV, AOH, and sequence variants from NGS
Simultaneous review of sequence variants, AOH, and CNVs
Request Demo

Why NxClinical?

1. Copy Number from NGS & Microarray

Powered with the gold-standard CNV calling algorithm for deriving copy number from NGS and Microarray, NxClinical allows consolidation of tests to provide CNV, AOH, and Seq Var from a single platform increasing production efficiencies and diagnostic yield. 

CNV from NGS

2. Support for all major instrument vendors for both NGS & Microarray

NxClinical is platform-agnostic and accepts data from various manufacturers and technologies including the latest platforms: Infinium GSA and CytoScan XON. 

platform agnostic word cloud

3. Integrated data and Visualization

A single system for analysis and interpretation of genomic aberrations from Microarray and NGS that includes a number of public resources to aid with interpretation such as OMIM® , DECIPHER, ClinGen/ClinVar, DGV, and CIViC.

Integrated data and Visualization

Customer Testimonials

Adoption of the NxClinical software has provided an efficient and secure workflow for our data batch loading and processing at our high volume clinical laboratory.

- Dr. Karine Hovanes, PhD, FACMG, Vice President of Scientific Advancement and Laboratory Director, Invitae
Dr. Karine Hovanes

Customer Testimonials

We were eager to be part of the Early Access program and try out NxClinical 4.1 Beta. We have been using NxClinical for many years and each release has features that we find really useful. BioDiscovery has also been very receptive to feedback from us on feature requests and we are happy to see many of those implemented in version 4.1 as they make our interpretation process even easier.

- Dr. Sharon Mexal, Senior Director of Clinical Operations, Ambry Genetics
Dr. Sharon Mexal

Customer Testimonials

My CAP/CLIA clinical lab has used BioDiscovery CNV software since 2012. I have evaluated many CNV analysis software programs and the BioDiscovery software always has been the best choice for my lab. I have watched the progression of their software development from Nexus Copy number to NxClinical 4.1 and have always been satisfied with their improvements. BioDiscovery listens to their customers and utilizes this information to improve and refine their software for clinical laboratories. NxClinical 4.1 continues to be intuitive to use, has a searchable database, and has new desirable features. I now use NxClinical 4.1 to analyze CNV data from the CytoScan XON array. I am able to define gene panels and only analyze the genes from a targeted list. Also, I like that NxClinical can be used to analyze NGS data to make CNV calls and I am in the process of evaluating this new feature.

- Todd Ackely, Manager, Michigan Molecular Genetics Laboratory (MMGL)
Todd Ackely

Customer Testimonials

At the UCSD clinical genetics lab, we are tasked with providing a complete and clinically actionable genomic profile of a patient's tumor. NxClinical allows us to do this rapidly and comprehensively by allowing us to consider CNV, LOH, and sequence variants together within a single software. The combined analysis facilitates interpretation in particular with double hit events while allowing us to save resources. In addition, the ability of NxClinical to call CNVs from NGS is an added bonus that will allow us to replace multiple assays with a single NGS assay for interrogation of all genomic variants.

- Dr. Sarah Murray, Director of Genomics Technologies, UC San Diego
Dr. Sarah Murray

Customer Testimonials

The functionality of NxClinical has allowed us to simplify and standardize our interpretation of CNVs across our group of Directors. This significantly reduces the time required to review the 10+ variants identified per genome.

- Dr. Lawrence Jennings, MD, PhD, Director, HLA and Molecular Diagnostic Labs at Northwestern Medicine
Dr. Larry Jennings

Request a Personalized Demonstration